Clincosm LogoSign in Get a demo

refractory neuroblastoma

Showing 1 - 23 of 23
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +44 more
  • Biopsy
  • +23 more
  • Birmingham, Alabama
  • +166 more
Feb 2, 2023

Malignant Solid Tumor, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma Trial in Puerto Rico, United States

Recruiting
  • Malignant Solid Neoplasm
  • +40 more
  • Biospecimen Collection
  • +6 more
  • Birmingham, Alabama
  • +172 more
Jan 27, 2023

Advanced Malignant Solid Tumor, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +31 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Birmingham, Alabama
  • +118 more
Jan 27, 2023

Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma Trial in Puerto Rico, United States (Ivosidenib)

Recruiting
  • Recurrent Ependymoma
  • +32 more
  • Birmingham, Alabama
  • +173 more
Jan 27, 2023

Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Neuroblastoma Trial in Bethesda, Seattle, Madison (Cyclophosphamide,

Recruiting
  • Recurrent Neuroblastoma
  • +3 more
  • Palo Alto, California
  • +3 more
Jan 25, 2023

Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
Jan 19, 2023

High Risk Neuroblastoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma Trial in Canada, United States (Dinutuximab,

Recruiting
  • High Risk Neuroblastoma
  • +4 more
  • Biospecimen Collection
  • +6 more
  • Los Angeles, California
  • +10 more
Jan 19, 2023

High Risk Neuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma Trial in Worldwide (Dinutuximab, Eflornithine

Recruiting
  • High Risk Neuroblastoma
  • +2 more
  • Dinutuximab
  • +4 more
  • Birmingham, Alabama
  • +141 more
Dec 28, 2022

Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma Trial (GPC2 CAR T cells)

Not yet recruiting
  • Refractory Neuroblastoma
  • +2 more
  • GPC2 CAR T cells
  • (no location specified)
Dec 21, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma Trial (Natural Killer Cells, Temozolomide, Irinotecan)

Recruiting
  • Relapsed Neuroblastoma
  • Refractory Neuroblastoma
  • Natural Killer Cells
  • +4 more
  • Columbus, Ohio
    Nationwide Children's Hospital
Oct 26, 2022

Advanced Malignant Solid Tumor, Recurrent Ependymal Tumor, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +35 more
  • Birmingham, Alabama
  • +108 more
Oct 19, 2022

CNS Embryonal Tumor With Rhabdoid Features, CNS Embryonal Tumor, Not Otherwise Specified, CNS Ganglioneuroblastoma Trial in

Active, not recruiting
Has Results
  • Central Nervous System Embryonal Tumor With Rhabdoid Features
  • +14 more
  • Birmingham, Alabama
  • +23 more
Oct 7, 2022

Neuroblastoma, Refractory Neuroblastoma, Relapsed Neuroblastoma Trial in Atlanta (Ex Vivo Expanded Allogeneic ?d T Cells in

Not yet recruiting
  • Neuroblastoma
  • +2 more
  • Ex Vivo Expanded Allogeneic γδ T Cells in Combination with Dinutuximab, Temozolomide, Irinotecan and Zoledronate
  • Atlanta, Georgia
    Children's Healthcare of Atlanta
Oct 6, 2022

Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Tumor, Lynch Syndrome Trial in Canada,

Withdrawn
  • Constitutional Mismatch Repair Deficiency Syndrome
  • +11 more
  • Biospecimen Collection
  • +2 more
  • Palo Alto, California
  • +8 more
Sep 9, 2022

Hematopoietic and Lymphoid Cell Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma Trial in Puerto Rico, United States

Recruiting
  • Hematopoietic and Lymphoid Cell Neoplasm
  • +37 more
  • Birmingham, Alabama
  • +171 more
Aug 24, 2022

Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +32 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Birmingham, Alabama
  • +124 more
Aug 24, 2022

Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial in Puerto

Recruiting
  • Malignant Solid Neoplasm
  • +26 more
  • Birmingham, Alabama
  • +121 more
Aug 24, 2022

Advanced Malignant Solid Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Trial

Recruiting
  • Advanced Malignant Solid Neoplasm
  • +30 more
  • Larotrectinib Sulfate
  • Birmingham, Alabama
  • +123 more
Aug 23, 2022

Neuroblastoma, Relapsed Neuroblastoma, Refractory Neuroblastoma Trial in United States (67Cu-SARTATE, 64Cu-SARTATE)

Recruiting
  • Neuroblastoma
  • +2 more
  • Phoenix, Arizona
  • +8 more
Jun 29, 2022

Advanced Malignant Solid Tumor, Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma, Ann Arbor Stage IV Childhood Non-Hodgkin

Active, not recruiting
  • Advanced Malignant Solid Neoplasm
  • +35 more
  • Birmingham, Alabama
  • +113 more
Jun 28, 2022

Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small

Recruiting
  • Desmoplastic Small Round Cell Tumor
  • +11 more
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jun 26, 2022

Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma Trial in Canada, United States (Onivyde, Talazoparib,

Recruiting
  • Recurrent Solid Tumor
  • +21 more
  • Palo Alto, California
  • +8 more
Jun 7, 2022

Relapsed Neuroblastoma, Refractory Neuroblastoma, Relapsed Osteosarcoma Trial in Houston (C7R-GD2.CART cells, Cyclophosphamide,

Recruiting
  • Relapsed Neuroblastoma
  • +6 more
  • C7R-GD2.CART cells
  • +2 more
  • Houston, Texas
  • +1 more
Nov 12, 2021